Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

BACKGROUND: Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of apoptotic cell death is a key mechanism of action of lapa...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:BMC Cancer
Main Authors: Eustace, Alex J, Conlon, Neil T, McDermott, Martina S J, Browne, Brigid C, O’Leary, Patrick, Holmes, Frankie A, Espina, Virginia, Liotta, Lance A, O’Shaughnessy, Joyce, Gallagher, Clair, O’Driscoll, Lorraine, Rani, Sweta, Madden, Stephen F, O’Brien, Neil A, Ginther, Charles, Slamon, Dennis, Walsh, Naomi, Gallagher, William M, Zagozdzon, Radoslaw, Watson, William R, O’Donovan, Norma, Crown, John
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6180577/
https://ncbi.nlm.nih.gov/pubmed/30305055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4852-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker